Akari Therapeutics Plc (CLA) News

Market on F-I-R-E! Every analyst, brokerage firm, news articles are scrambling over themselves to explain why this BULL MARKET is only 2 years old and has decades to go. They have determined the Covid disruption and extreme snap back was a new bull run. Funny but when I look at a long term chart I

To reinforce Tesla's veer issue, that seems to impact vehicles with/without AP enabled & every model and year, here are a few incidents that showcase Teslas behave just like that Vinfast EV the NHTSA is investigating (EVs are more dangerous than ICE!). I suspect that Tesla's emergency lane departure

I was watching that all day. I have a buy order in for 3 mil at .0001. Kept watching those 10 share trades. Looked at market maker signals. Found one site that said it could be a market maker trying to bring awareness or to watch out for. Also said making small trades is a way to keep the price low

You should have followed up on reimbursement. Why has that not been submitted 4 years since data lock? Do they not want to make any money post approval.

It's my understanding we are at bottom and the only direction form here is up for some of these companies. I understand Buffet owns a large stake in LAAC. I'm up 35%.

Do you think well get news for the last 2 months. December is holiday season and people take vacations.

https://media.stocktwits-cdn.com/api/3/media/23421/default.png...IMO, this is a good news piece of information. This is the "BIGS". Hope all who have been to one of these heavy hitters set up shows agree.

We recognize we are a small fish in a big pond. Our pond is WW w/possible (TBD)

OTCN at it

LJ, I won't be around the computer this weekend that much, if you see or hear anything about this ticker let me know please. I will however from time to time will peak through my phone and see if something new came up with SMCI and I will on the look out for your reply. Have a good day and great w

Money for nothing, but these guy pay big money for the later. I bet none of them have any game. lol...

Doc,

I recall you mentioned that inhibiting PD1 is better than inhibiting PD-L1. I could remember it wrong.

One thing I want to mention is that Amgen loves PD1 inhibitor and it has biosimilars to both keytruda and Opdivo under p3 trials.

Baker Brothers lo

Someone please just pump this to the moon so we can get out of this scam

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Making Strong Statement in Multicommodity Mineral Space
https://www.miningnewswire.com/renforth-resources-inc-cse-rfr-otcqb-rfhrf-making-strong-statement-in-multicommodity-mineral-space/#:~:text=Multicommodity%20Mineral%20Space-,Renforth%20Re

Part A is not placebo controlled, only Part B is.

We don't know the breakdown of subjects in each part. I agree that the number in Part B is going to be small no matter how it breaks down.

We shall see how it turns out.

If both patients have complete regression, $600m -1b market cap…. $35/share +

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Making Strong Statement in Multicommodity Mineral Space
https://www.miningnewswire.com/renforth-resources-inc-cse-rfr-otcqb-rfhrf-making-strong-statement-in-multicommodity-mineral-space/#:~:text=Multicommodity%20Mineral%20Space-,Renforth%20Res

Wonder if Phil E Wood has any workings with INVO Biosciece and Wood Violet Fertility Clinic LLC. Looks like he’s a shareholder involved in the Immune Bankruptcy case.

That is true. And having to watch your parents break up in public can't be fun...

Flaskworks will not be approved in 2025 for commercial production. Your buddy Doc logic still forecasts an annual revenue of $90M during the first year post UK approval.

You are welcome Tredenwater. Keep in mind that most NCE applications include data from 2 properly-sized Phase 3 trials. The single small P2b/P3 trial is what introduces risk into EMA and FDA applications for 2-73. You think you know the statistics but you don't - none of us know the statistics fo

It will be offset as preferred shares which will also Represent control shares and company ownership

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

Source: GlobeNewswire Inc.

T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited fin

Fun day: up 18% first thing in AM, then down 16%, only to pop back up for a 4% gain at the end of the day. Must remember to keep powder dry and trigger finger limber for another one like that.

15 different 10 share trades at .0001? .001 per trade? Not your typical penny stock I guess … sigh

Yes, that's true.